During the West African Ebola outbreak that began in 2013, an experimental biopharmaceutical drug called ZMappTM was a glimmer of hope in the midst of a health crisis. Now, scientists at Texas Biomedical Research Institute in San Antonio have been awarded a $2 million dollar contract by the makers of ZMapp, Mapp Biopharmaceutical, Inc., to further test this promising new therapeutic.
The researchers will spend the next five years collecting data from Ebola and Lassa survivors to learn how they fought off the virus.
Scientists at The Scripps Research Institute have discovered the workings of the first promising treatment for Marburg virus, a pathogen with the same pandemic potential as Ebola virus.
Survivors of the first known Ebola outbreak, which occurred in the Democratic Republic of the Congo in 1976, may be key to development of vaccines and therapeutic drugs to treat future outbreaks
Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease. The results come from one of the most in-depth studies ever of blood samples from patients with Ebola.
In a comprehensive and complex molecular study of blood samples from Ebola patients in Sierra Leone, published today (Nov. 16, 2017) in Cell Host and Microbe, a scientific team led by the University of Wisconsin–Madison has identified signatures of Ebola virus disease that may aid in future treatment efforts.
Rural counties continue to rank lowest among counties across the U.S., in terms of health outcomes. A group of national organizations including the Robert Wood Johnson Foundation and the National 4-H Council are leading the way to close the rural health gap.
A new study by researchers has identified an innovative strategy for treating influenza, and perhaps other infectious diseases as well. Scientists showed that a small protein called retrocyclin-101 (RC-101) could potentially improve the symptoms and mortality associated with the flu and possibly other types of infectious illness as well.
A collaboration among research institutions, private industry, and the US Government will develop a tetravalent vaccine to protect against four viruses that can be fatal
Utilizing messages focused on images created by local artists and written information communicated through local dialects proved essential to counter misperceptions during the Ebola epidemic in Sierra Leone, according to a study conducted in part by Muriel J. Harris, Ph.D., associate professor, University of Louisville School of Public Health and Information Sciences, Department of Health Promotion and Behavior Sciences.
Biological “detectives” are tracking down biothreats such as the bacteria that causes tularemia (“rabbit fever”), but they constantly face the challenge of avoiding false positives.
Scientists have pinpointed how a tiny protein seems to make the deadly Ebola virus particularly contagious.
The NIH has awarded Einstein researchers three grants totaling more than $12 million to protect against three deadly viruses—Ebola, Marburg and hantavirus. Research collaborations between Kartik Chandran, Ph.D., professor of microbiology & immunology and the Harold and Muriel Block Faculty Scholar in Virology, and Jonathan Lai, Ph.D., associate professor of biochemistry, have led to novel approaches for developing vaccines and treatments.
Researchers at the University of North Carolina at Chapel Hill have found Ebola RNA in the semen of survivors two years after infection. They are calling on the World Health Organization to update its guidelines on sexual transmission.
Three years after an Ebola epidemic swept across West Africa, researchers have found a clue to how the virus may live on in the eyes of survivors suffering from uveitis – one of the more serious and common complications of the disease.
The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.
Scientists at The Scripps Research Institute (TSRI) have shown that for the virus that causes the flu, two wrongs can sometimes make a right.
Research done at Argonne National Laboratory’s Advanced Photon Source was vital to the process of identifying the structure, which provides a guide for designing a Lassa virus vaccine. Lassa virus is endemic to Africa and kills thousands of people a year; it is particularly deadly for pregnant women.
Zika viral load and the degree of Zika symptoms during pregnancy are not necessarily associated with problems during pregnancy or fetal abnormalities at birth. The presence of antibodies to previously acquired dengue fever also is not necessarily linked to abnormalities during pregnancy or at birth.
A team of scientists in the Pacific Northwest has solved the 3-D structure of 1,000 proteins from more than 70 organisms that cause infectious disease in people. The proteins come from microbes that cause several serious diseases, including tuberculosis, Listeria, Giardia, Ebola, anthrax, C. diff., Legionella, Lyme, chlamydia and the flu.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right